Brevan Howard Capital Management’s CRISPR Therapeutics CRSP Stock Holding History

Brevan Howard Capital Management’s Portfolio CRSP Stock Details CRSP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$680K	Buy	12,459 +6,823	+121%	+$360K	0.01%	1277
2026 Q1	$268K	Buy	+5,636	New	+$297K	﹤0.01%	1697
2024 Q4	–	Sell	-4,595	Closed	-$216K	–	1105
2024 Q3	$216K	Buy	+4,595	New	+$233K	﹤0.01%	972
2024 Q1	–	Sell	-5,812	Closed	-$364K	–	1059
2023 Q4	$364K	Buy	+5,812	New	+$321K	﹤0.01%	630
2021 Q2	–	Sell	-14,911	Closed	-$1.82M	–	43
2021 Q1	$1.82M	Sell	14,911 -8,289	-36%	-$1.25M	0.27%	46
2020 Q4	$3.55M	Buy	+23,200	New	+$2.74M	0.71%	24

Other funds holding CRSP

AIM

ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

OAG

Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

GSK plc London $602M AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

SOCM

SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Brevan Howard Capital Management's CRSP Position: Q2 2026 in Review

Brevan Howard Capital Management increased its CRISPR Therapeutics (CRSP) stake by 121% in Q2 2026, buying an estimated $360K and bringing the position to 12,459 shares worth $680K. The position accounts for 0.01% of the portfolio, ranked #1277.

Brevan Howard Capital Management first reported a position in CRSP in Q4 2020 and has held it in 6 quarters since. The position peaked at $3.55M in Q4 2020. 521 funds tracked by Wall St. Rank hold CRSP as of Q2 2026.

Brevan Howard Capital Management held 12,459 shares of CRISPR Therapeutics worth $680K as of Q2 2026.
Brevan Howard Capital Management bought 6,823 CRISPR Therapeutics shares in Q2 2026, an estimated $360K.
CRISPR Therapeutics made up 0.01% of Brevan Howard Capital Management's portfolio in Q2 2026, its #1277 holding.
Brevan Howard Capital Management first reported a position in CRISPR Therapeutics in Q4 2020 and has held it in 6 quarters since.
Brevan Howard Capital Management's CRISPR Therapeutics position peaked at $3.55M in Q4 2020.
521 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q2 2026.

Based on Brevan Howard Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.